MedTrace Logo

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

NCT01629732 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-05-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

Conditions

  • Hepatitis C Virus

Interventions

DRUG

Daclatasvir

Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks

DRUG

Daclatasvir

Film coated tablet, Oral, 60 mg, Once daily, 24 weeks

DRUG

BMS-986094

Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks

DRUG

BMS-986094

Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks

DRUG

BMS-986094

Capsule, Oral, 200 mg, Once daily, 24 Weeks

DRUG

Ribavirin

Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks

DRUG

Placebo for BMS-986094

Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-02-28
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01629732 on ClinicalTrials.gov